(Q36510464)

14 August 2017

1 reference

title

Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications (English)

1 reference

14 August 2017

Rhian M Touyz

1

1 reference

PubMed ID

16782410

14 August 2017

Ernesto L Schiffrin

series ordinal

2

1 reference

14 August 2017

16 June 2006

1 reference

14 August 2017

Vascular Pharmacology

1 reference

14 August 2017

45

1 reference

14 August 2017

1

1 reference

14 August 2017

19-28

1 reference

GATA-6 is involved in PPARgamma-mediated activation of differentiated phenotype in human vascular smooth muscle cells

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptors in the cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

New targets for PPARgamma in the vessel wall: implications for restenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

PPARdelta is a very low-density lipoprotein sensor in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptors in inflammation control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptors: nuclear control of metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Increased expression of peroxisome proliferator-activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Endothelin-1 attenuates omega3 fatty acid-induced apoptosis by inhibition of caspase 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Phosphorylation of PPARs: from molecular characterization to physiological relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Corrigendum to “The PPARδ agonist GW0742X reduces atherosclerosis in LDLR−/− mice” [Atherosclerosis 181 (2005) 29–37]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor delta (PPARdelta )-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Pioglitazone improves left ventricular diastolic function in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Antiinflammatory and antiarteriosclerotic effects of pioglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Cloning of novel members of the steroid hormone receptor superfamily.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Selling safety--lessons from muraglitazar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Differential expression and activation of a family of murine peroxisome proliferator-activated receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

PPARgamma and atherosclerosis: effects on cell growth and movement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Transcriptional repression of atherogenic inflammation: modulation by PPARdelta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Activation of PPARdelta alters lipid metabolism in db/db mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

PPAR gamma and the treatment of insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptors and cardiovascular remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Critical roles of PPAR beta/delta in keratinocyte response to inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-γ Agonist in Hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

15-Deoxy-prostaglandin J(2) inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPAR gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.014

10.1016/J.VPH.2005.11.014

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16782410